

DYNAVAX TECHNOLOGIES CORP  
Form 8-K  
September 21, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**Current Report**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2011

**Dynavax Technologies Corporation**

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware  
(State or other jurisdiction)

33-0728374  
(IRS Employer)

Edgar Filing: DYNAVAX TECHNOLOGIES CORP - Form 8-K

of incorporation)

Identification No.)

2929 Seventh Street, Suite 100

Berkeley, CA 94710-2753

(Address of principal executive offices, including zip code)

(510) 848-5100

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On September 18, 2011, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Reports Complete Results from the HEPLISAV Phase 3 Trial in Healthy Adults Over Age 40" and presented complete results for the entire study population of its Phase 3 trial (HBV-16) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL. A copy of the press release and the presentation are attached as Exhibit 99.1 and 99.2, respectively, to this current report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibit

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated September 18, 2011, titled "Dynavax Reports Complete Results from the HEPLISAV Phase 3 Trial in Healthy Adults Over Age 40"
99.2	Dynavax's Oral Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DYNAVAX TECHNOLOGIES CORPORATION**

Date: September 21, 2011

By: /s/ Michael S. Ostrach  
Michael S. Ostrach  
Vice President

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated September 18, 2011, titled Dynavax Reports Complete Results from the HEPLISAV Phase 3 Trial in Healthy Adults Over Age 40
99.2	Dynavax's Oral Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)